Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards Sees ‘Tough Time’ Ahead For TAVR Patients

Executive Summary

The COVID-19 pandemic is severely hindering patient access to transcatheter aortic valve replacement procedures. Edwards Lifesciences, the market leader, is hopeful that TAVR volumes will recover by the end of 2020, but that will be too late for many patients.

You may also be interested in...



Edwards Beat Analysts' And Its Own Projections in Q2 As TAVR Volumes Recover

The company recorded $925m in revenue in the second quarter of 2020, exceeding the top end of its previous guidance, and expects to return to growth by the end of the year.

Cardiology Device Lobbyists Focused On Reimbursement, Coronavirus, Trade Issues In Early 2020

Cardiology device firms relied primarily on in-house lobbyists but also recruited external groups to sway lawmakers to adopt favorable positions on reimbursement, COVID-19, international trade and other issues from January-March 2020, says this Medtech Insight analysis.

Edwards Receives CE Mark For PASCAL Transcatheter Tricuspid Valve Repair System

Edwards Lifesciences received the CE mark for its PASCAL transcatheter system for treating triscupid valve regurgitation, competing against Abbott’s newly CE-marked TriClip. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel